Watch a VC Grill Two AI-Biotech Founders — Live

One built technology that contributed to a Nobel Prize. The other found cancer drug targets hiding in public data that the entire pharmaceutical industry missed.

Both are building companies that couldn't have existed five years ago — where AI designs the molecule, the lab validates it, and the validation trains a better model. What used to take years now runs in weeks.

On March 24th, they're sitting down with their investor — Anthony Atlas, ISEF 1st Place winner and founder of Science Fair Fund — to show you exactly how it works. Live. Unscripted. With open Q&A.

These deals move fast. The founders building at this frontier don't do public events. This is a rare window into two companies at the cutting edge of AI-biotech - before they become inaccessible.

Science Fair Fund is building a portfolio of pre-seed bets on science fair alumni - a cohort that has quietly produced some of the most exceptional technical founders of the last two decades.

This session is designed for a small, serious group of accredited investors evaluating the fund. If you're exploring venture as an asset class, or looking for exposure to Deep Tech and AI-biotech at the earliest stage, this is your entry point.

Anthony is an International Science and Engineering Fair (ISEF) 1st Place winner and multi-year Grand Awards judge with deep roots in the science fair ecosystem. As an operator, he's raised over $75M in venture capital and helped scale three deep-tech companies from seed to Series B.

Both featured founders are Science Fair Fund portfolio companies. They met through the fund's network and are now collaborating on real science together. This is what a thesis-driven fund looks like when it actually works.

Science Fair Fund is a $5M pre-seed fund focused exclusively on science fair alumni building Deep Tech, AI, and Biotech companies. The fund targets a cohort of founders who've been building, testing, and defending their ideas in front of judges since high school — and are now applying that rigor to real companies.

The fund operates on Decile - institutional-grade infrastructure for fund operations, compliance, reporting, and LP relations. Your investment experience is handled by the same platform trusted by a growing cohort of emerging venture managers nationwide.

SEATS ARE LIMITED 

This isn't a replay-it-later webinar. It's a live, interactive session with real founders and real Q&A. If you're an accredited investor evaluating venture exposure - or just want to see what AI-first biotech actually looks like from the inside — this is the hour to block.